Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis ; volume:9 ; number:1 ; day:19 ; month:10 ; year:2023 ; pages:1-9 ; date:12.2023
npj Parkinson's Disease ; 9, Heft 1 (19.10.2023), 1-9, 12.2023
- Creator
-
Sako, Wataru
Kogo, Yuki
Koebis, Michinori
Kita, Yoshiaki
Yamakage, Hajime
Ishida, Takayuki
Hattori, Nobutaka
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41531-023-00589-8
- URN
-
urn:nbn:de:101:1-2024020808513487824756
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 2:33 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sako, Wataru
- Kogo, Yuki
- Koebis, Michinori
- Kita, Yoshiaki
- Yamakage, Hajime
- Ishida, Takayuki
- Hattori, Nobutaka
- SpringerLink (Online service)
Other Objects (12)
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
Helicobacter pylori infection and Parkinson’s Disease: etiology, pathogenesis and levodopa bioavailability
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
Charakteristika der Unified Parkinson’s Disease Rating Scale im Rahmen der Levodopa-Response
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
Helicobacter pylori infection and Parkinson’s Disease: etiology, pathogenesis and levodopa bioavailability
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
Charakteristika der Unified Parkinson’s Disease Rating Scale im Rahmen der Levodopa-Response
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
Helicobacter pylori infection and Parkinson’s Disease: etiology, pathogenesis and levodopa bioavailability
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease